Variables | N (%) or mean ± SD | HFS-14 score (or ρ) | P-value |
Gender | |||
Male | 55 (52.4) | 20.3 ± 18.3 | 0.51 |
Female | 50 (47.6) | 22.8 ± 22.0 | |
Age, y* | 62.3 ± 12.0 | 0.05 | 0.60 |
Employment status | |||
Employed | 38 (36.2) | 27.6 ± 24.1 | 0.03 |
Unemployed | 67 (63.8) | 18.0 ± 16.6 | |
Education | |||
≤12 years | 70 (66.7) | 22.7 ± 20.9 | 0.35 |
12 years | 35 (33.3) | 19.1 ± 18.2 | |
Cohabitation status | |||
Living with family or other adults | 99 (94.3) | 21.2 ± 19.3 | 0.67 |
Living alone | 6 (5.7) | 27.0 ± 31.9 | |
ECOG performance status | |||
0 | 81 (77.1) | 23.4 ± 21.8 | 0.01 |
1 or 2 | 24 (22.9) | 15.3 ± 11.1 | |
Type of cancer | |||
Breast cancer | 35 (33.3) | 24.4 ± 20.3 | 0.22 |
Colorectal cancer | 30 (28.6) | 15.5 ± 13.1 | |
Hepatocellular carcinoma | 31 (29.5) | 22.2 ± 25.0 | |
Renal cell carcinoma | 9 (8.6) | 27.8 ± 17.5 | |
Anti-cancer agent | |||
Capecitabine | 65 (61.9) | 20.3 ± 17.8 | 0.46 |
Sorafenib or Sunitinib | 40 (38.1) | 23.5 ± 23.5 | |
Time since treatment, months* | 4.6 ± 5.7 | 0.19 | 0.05 |
Depressive symptoms | |||
Yes | 32 (30.5) | 37.9 ± 22.3 | <0.0001 |
No | 73 (69.5) | 15.5 ± 15.5 | |
Self-care score for hand foot syndrome | 25.8 ± 7.5 | −0.21 | 0.02 |